BioMark Diagnostics Announces Expansion of Its Specialty Laboratory Services in Quebec to Accommodate Increased Demand from International Partnerships
BioMark Diagnostics (OTCQB: BMKDF), a liquid biopsy test developer, has completed a strategic laboratory equipment leasing agreement that doubles its testing capacity in Quebec. This expansion supports the upcoming commercial launch of its metabolomic-based lung cancer diagnostic assay and enhances the company's ability to provide advanced diagnostic analytical molecular services.
The upgraded facility will serve as a certified and accredited laboratory, enabling broad deployment through clinical partnerships, centralized testing services, and expanded contract research programs. The expansion positions BioMark to meet increasing global demand for non-invasive liquid biopsy diagnostics and supports research collaborations with healthcare institutions and pharmaceutical companies.
BioMark Diagnostics (OTCQB: BMKDF), sviluppatore di test di biopsia liquida, ha completato un accordo strategico di leasing di attrezzature di laboratorio che raddoppia la sua capacità di test in Quebec. Questa espansione supporta il prossimo lancio commerciale del suo test diagnostico del cancro ai polmoni basato sul metabolomica e migliora la capacità dell'azienda di offrire servizi avanzati di analisi molecolare diagnostica.
La struttura potenziata fungerà da laboratorio certificato e accreditato, consentendo una vasta diffusione tramite partnership cliniche, servizi di test centralizzati e programmi di ricerca a contratto ampliati. L'espansione posiziona BioMark per soddisfare la crescente domanda globale di diagnostica non invasiva tramite biopsia liquida e supporta collaborazioni di ricerca con istituzioni sanitarie e aziende farmaceutiche.
BioMark Diagnostics (OTCQB: BMKDF), desarrollador de pruebas de biopsia líquida, ha completado un acuerdo estratégico de arrendamiento de equipos de laboratorio que duplica su capacidad de pruebas en Quebec. Esta expansión respalda el próximo lanzamiento comercial de su ensayo diagnóstico de cáncer de pulmón basado en metabolómica y mejora la capacidad de la empresa para ofrecer servicios avanzados de análisis molecular diagnóstico.
La instalación mejorada funcionará como un laboratorio certificado y acreditado, permitiendo una amplia implementación a través de asociaciones clínicas, servicios de pruebas centralizados y programas ampliados de investigación por contrato. La expansión posiciona a BioMark para satisfacer la creciente demanda global de diagnósticos no invasivos de biopsia líquida y apoya colaboraciones de investigación con instituciones de salud y compañías farmacéuticas.
BioMark Diagnostics (OTCQB: BMKDF)는 액체 생검 검사 개발업체로서, 퀘벡에서 검사 용량을 두 배로 늘리는 전략적 실험실 장비 임대 계약을 완료했습니다. 이번 확장은 대사체 기반 폐암 진단 검사 상업 출시를 지원하며, 회사의 고급 진단 분자 분석 서비스 제공 능력을 향상시킵니다.
업그레이드된 시설은 인증 및 공인된 실험실로서 기능하여 임상 파트너십, 중앙 집중식 검사 서비스, 확대된 계약 연구 프로그램을 통해 광범위한 배포가 가능해집니다. 이번 확장은 BioMark가 비침습적 액체 생검 진단에 대한 전 세계적인 수요 증가에 대응하고, 의료 기관 및 제약사와의 연구 협력을 지원하는 데 기여합니다.
BioMark Diagnostics (OTCQB : BMKDF), développeur de tests de biopsie liquide, a conclu un accord stratégique de location d’équipements de laboratoire qui double sa capacité de test au Québec. Cette expansion soutient le lancement commercial prochain de son test diagnostique du cancer du poumon basé sur la métabolomique et améliore la capacité de l'entreprise à fournir des services analytiques moléculaires diagnostiques avancés.
Les installations améliorées serviront de laboratoire certifié et accrédité, permettant un déploiement étendu via des partenariats cliniques, des services de tests centralisés et des programmes de recherche sous contrat élargis. Cette expansion positionne BioMark pour répondre à la demande mondiale croissante en diagnostics non invasifs par biopsie liquide et soutient les collaborations de recherche avec des institutions de santé et des entreprises pharmaceutiques.
BioMark Diagnostics (OTCQB: BMKDF), ein Entwickler von Flüssigbiopsie-Tests, hat eine strategische Vereinbarung zum Leasing von Laborausrüstung abgeschlossen, die seine Testkapazität in Quebec verdoppelt. Diese Erweiterung unterstützt die bevorstehende kommerzielle Einführung seines metabolombasierten Lungenkrebs-Diagnosetests und verbessert die Fähigkeit des Unternehmens, fortschrittliche diagnostische molekulare Analysedienste anzubieten.
Die aufgerüstete Einrichtung wird als zertifiziertes und akkreditiertes Labor dienen, was eine breite Anwendung durch klinische Partnerschaften, zentralisierte Testdienste und erweiterte Vertragsforschungsprogramme ermöglicht. Die Expansion positioniert BioMark, um der steigenden globalen Nachfrage nach nicht-invasiven Flüssigbiopsie-Diagnostika gerecht zu werden und unterstützt Forschungskooperationen mit Gesundheitseinrichtungen und Pharmaunternehmen.
- Strategic equipment leasing agreement doubles testing capacity
- Positions for commercial launch of lung cancer diagnostic assay
- Expands capabilities for international pharmaceutical and biotech partnerships
- Enhanced platform for clinical validation studies and regulatory filings
- Facilitates deployment of multiple new assays
- Laboratory certification and accreditation still pending
- Significant operational costs from equipment leasing agreement
Expansion of BioMark brings advanced equipment and doubles capacity, accelerating commercialization of lung cancer assay
Vancouver, British Columbia--(Newsfile Corp. - August 5, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy tests for early cancer detection, announces today the completion of a strategic laboratory equipment leasing agreement, substantially doubling BioMark's testing capacity and positioning the Company for the imminent commercial launch of its lung cancer assay. This critical advancement in its operational capabilities solidifies the expansion of its diagnostic and research services and positions the Company as a central hub for innovation, high-throughput diagnostics, and collaborative ventures.
Accelerating Commercialization and Market Entry for Life-Saving Diagnostics
The newly acquired state-of-the-art laboratory equipment is aligned with BioMark's commercialization strategy. This enhanced capacity directly addresses the escalating global demand for non-invasive liquid biopsy diagnostics and, crucially, prepares the Company for the widespread clinical deployment of its metabolomic-based lung cancer diagnostic assay. The expansion also facilitates the provision of advanced diagnostic analytical molecular services to international clients and significantly expands its research capabilities to accommodate the growing needs of metabolomics from pharmaceutical and biotechnology companies. Furthermore, this initiative supports the accelerated rollout of multiple new assays, aligning with the company's laboratory certification and accreditation roadmap.
"Our enhanced laboratory capacity underscores BioMark's unwavering commitment to clinical excellence, innovation, and accessibility," stated Jean-Francois Haince, CSO and GM of BioMark Diagnostic Solutions. "Once certified, this laboratory will serve as a pivotal engine for commercialization, revenue generation, strategic partnerships, and the widespread clinical deployment of our metabolomic-based diagnostic assays."
Creating a Platform for Scalable Growth and Strategic Value
This strategic laboratory upgrade aligns with BioMark's vision to establish an agile, clinically robust platform capable of supporting research on advanced cancer. It will also facilitate ongoing clinical research collaborations with global healthcare institutions and pharmaceutical companies, while streamlining regulatory filings and clinical validation studies for new indications and expansion into international markets. BioMark's forthcoming certified and accredited laboratory will be instrumental in enabling a broad deployment strategy through robust clinical partnerships, centralized testing services, and expanded contract research programs.
"Our team remains intensely focused on achieving key milestones and enhancing long-term shareholder value," added Rashid Ahmed Bux, President & CEO of BioMark. "This accomplishment strategically positions BioMark at a significant advantage within the diagnostic arena, marking a critical enabler as we continue to scale our AI-enhanced assays and foster collaborations across the entire cancer care spectrum. We are now well-equipped to meet the anticipated demand for our innovative solutions and drive significant growth."
About BioMark Diagnostics Inc.
BioMark Diagnostics Inc. is a leading developer of liquid biopsy tests for the early detection of cancer that leverages the power of metabolomics and machine learning algorithms. The company's proprietary technology utilizes a simple blood draw to detect the presence of cancer-associated biomarkers, enabling earlier diagnosis and improved patient outcomes. The technology can also be used for measuring response to treatment and potentially for serial monitoring of cancer survivors. BioMark is committed to developing innovative and accessible diagnostic solutions to address unmet medical needs in oncology.
Further information about BioMark is available under its profile on the SEDAR+ website www.sedarplus.ca and the CSE website https://thecse.com/.
For further information on BioMark, please Contact:
Rashid Ahmed Bux
President & CEO
BioMark Diagnostics Inc.
Tel. 604-370-0779
Email: info@biomarkdiagnostics.com
Forward-Looking Information:
This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events, or results or otherwise, other than as required by applicable securities laws.
The CSE has not reviewed, approved, or disapproved of the content of this press release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/261250
FAQ
What is the significance of BioMark's (BMKDF) laboratory expansion in Quebec?
How will the new laboratory equipment affect BioMark's (BMKDF) operations?
What are the main benefits of BioMark's (BMKDF) laboratory expansion for cancer diagnostics?
When will BioMark's (BMKDF) expanded laboratory be fully operational?
How does the laboratory expansion align with BioMark's (BMKDF) growth strategy?
